Jacobi Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.04M | Buy |
1,673
+39
| +2% | +$26.5K | 0.05% | 301 |
|
|
2026
Q1 | $1.26M | Buy |
1,634
+23
| +1% | +$17.6K | 0.07% | 257 |
|
|
2025
Q4 | $1.24M | Buy |
1,611
+9
| +0.6% | +$6.11K | 0.07% | 250 |
|
|
2025
Q3 | $901K | Buy |
1,602
+168
| +12% | +$95K | 0.05% | 290 |
|
|
2025
Q2 | $753K | Buy |
1,434
+9
| +0.6% | +$5.02K | 0.05% | 304 |
|
|
2025
Q1 | $904K | Buy |
1,425
+107
| +8% | +$73.6K | 0.07% | 267 |
|
|
2024
Q4 | $939K | Buy |
1,318
+21
| +2% | +$17.6K | 0.07% | 256 |
|
|
2024
Q3 | $1.36M | Buy |
1,297
+72
| +6% | +$80.1K | 0.1% | 191 |
|
|
2024
Q2 | $1.29M | Buy |
1,225
+86
| +8% | +$83.4K | 0.11% | 175 |
|
|
2024
Q1 | $1.1M | Buy |
1,139
+20
| +2% | +$19K | 0.1% | 188 |
|
|
2023
Q4 | $983K | Buy |
1,119
+106
| +10% | +$87.3K | 0.1% | 192 |
|
|
2023
Q3 | $834K | Buy |
1,013
+6
| +0.6% | +$4.71K | 0.09% | 201 |
|
|
2023
Q2 | $724K | Sell |
1,007
-451
| -31% | -$348K | 0.08% | 223 |
|
|
2023
Q1 | $1.2M | Buy |
1,458
+35
| +2% | +$26.4K | 0.14% | 148 |
|
|
2022
Q4 | $1.03M | Sell |
1,423
-3
| -0.2% | -$2.21K | 0.13% | 162 |
|
|
2022
Q3 | $982K | Buy |
1,426
+46
| +3% | +$29K | 0.13% | 156 |
|
|
2022
Q2 | $816K | Buy |
1,380
+205
| +17% | +$133K | 0.11% | 185 |
|
|
2022
Q1 | $821K | Buy |
1,175
+25
| +2% | +$15.8K | 0.1% | 194 |
|
|
2021
Q4 | $726K | Buy |
1,150
+20
| +2% | +$12.3K | 0.09% | 208 |
|
|
2021
Q3 | $684K | Buy |
1,130
+46
| +4% | +$28.6K | 0.09% | 196 |
|
|
2021
Q2 | $605K | Buy |
1,084
+1,030
| +1,907% | +$522K | 0.08% | 204 |
|
|
2021
Q1 | $26K | Sell |
54
-47
| -47% | -$22.9K | ﹤0.01% | 726 |
|
|
2020
Q4 | $49K | Hold |
101
| – | – | 0.01% | 537 |
|
|
2020
Q3 | $57K | Hold |
101
| – | – | 0.01% | 468 |
|
|
2020
Q2 | $63K | Hold |
101
| – | – | 0.01% | 434 |
|
|
2020
Q1 | $49K | Sell |
101
-10
| -9% | -$4.13K | 0.01% | 423 |
|
|
2019
Q4 | $42K | Hold |
111
| – | – | 0.01% | 494 |
|
|
2019
Q3 | $31K | Hold |
111
| – | – | 0.01% | 531 |
|
|
2019
Q2 | $35K | Hold |
111
| – | – | 0.01% | 508 |
|
|
2019
Q1 | $46K | Buy |
111
+20
| +22% | +$8.24K | 0.01% | 424 |
|
|
2018
Q4 | $34K | Hold |
91
| – | – | 0.01% | 442 |
|
|
2018
Q3 | $37K | Buy |
91
+87
| +2,175% | +$33.1K | 0.01% | 471 |
|
|
2018
Q2 | $1K | Hold |
4
| – | – | ﹤0.01% | 982 |
|
|
2018
Q1 | $1K | Hold |
4
| – | – | ﹤0.01% | 948 |
|
|
2017
Q4 | $1K | Sell |
4
-20
| -83% | -$8.1K | ﹤0.01% | 895 |
|
|
2017
Q3 | $11K | Hold |
24
| – | – | ﹤0.01% | 626 |
|
|
2017
Q2 | $12K | Buy |
24
+20
| +500% | +$8.75K | ﹤0.01% | 539 |
|
|
2017
Q1 | $2K | Buy |
+4
| New | +$1.48K | ﹤0.01% | 640 |
|
|
2016
Q4 | – | Sell |
-4
| Closed | -$2K | – | 684 |
|
|
2016
Q3 | $2K | Hold |
4
| – | – | ﹤0.01% | 652 |
|
|
2016
Q2 | $1K | Buy |
+4
| New | +$1.54K | ﹤0.01% | 688 |
|
Other funds holding REGN
MCI
Jacobi Capital Management's REGN Position: Q2 2026 in Review
Jacobi Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 2.4% in Q2 2026, buying an estimated $26.5K and bringing the position to 1,673 shares worth $1.04M. The position accounts for 0.05% of the portfolio, ranked #301.
Jacobi Capital Management first reported a position in REGN in Q2 2016 and has held it in 40 quarters since. The position peaked at $1.36M in Q3 2024. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Jacobi Capital Management held 1,673 shares of Regeneron Pharmaceuticals worth $1.04M as of Q2 2026.
- Jacobi Capital Management bought 39 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $26.5K.
- Regeneron Pharmaceuticals made up 0.05% of Jacobi Capital Management's portfolio in Q2 2026, its #301 holding.
- Jacobi Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
- Jacobi Capital Management's Regeneron Pharmaceuticals position peaked at $1.36M in Q3 2024.
- 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Jacobi Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.